EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    What Changes at Scale, and How Do You Know?

    A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...

KNOWLEDGE BANK

TOP ARTICLES

press releases Read more...

Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development

Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX a potential firstinclass small molecule modulator of MYC condensates into clinical development

Instem and Histofy Launch Provantis® Compose, Accelerating Nonclinical Study Reporting Through AI-Assisted Automation and Expert Oversight

Instem a leading provider of software for life sciences research and regulatory operations across preclinical and clinical RD today announced a strategic partnership with Histofy to launch Provantis Compose a powerful new module designed to automate and accelerate the creation of final study reports...

Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion

Rosemont Pharmaceuticals Holdings Inc Rosemont a global specialty pharmaceutical company focused on designing and delivering medicines around patients needs today announced that it has entered into a definitive merger agreement

Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola

Asimov the company building an AInative synthetic biology platform to advance therapeutic development and Emergent Biosolutions NYSE EBS a leading global public health company today announced a cell line development partnership

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

25 - 25

Nov 2026

What’s Next for Pharma Marketing in 2027

Landesmuseum Zürich, Zurich, S...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

LATEST NEWS Read more...

Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer

Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS

Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications

Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU

FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer

Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer

European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer

Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...

Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer

Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN

Takeda Launches ORZEYFUL (Oveporexton), the First Orexin Agonist for Narcolepsy Type 1, in the US

Takeda TSE NYSE TAK has announced the US launch of ORZEYFUL oveporexton CIV now available by prescription for adults with narcolepsy type NT also known as narcolepsy with cataplexy The medicine is the first and only orexin agonist available for this condition